Trial reportJournal of neuroengineering and rehabilitation2022
Effects of ATLAS 2030 gait exoskeleton on strength and range of motion in children with spinal muscular atrophy II: a case series.
Trial report in Journal of neuroengineering and rehabilitation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04837157 (Evaluation of the Safety of ATLAS 2030 in the Application of Robot-assisted Physical Therapy to Children With Neuromuscular Diseases Phase I), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Safety of ATLAS 2030 in the Application of Robot-assisted Physical Therapy to Children With Neuromuscular Diseases Phase I
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The assistive gait devices and their implementation in activities of daily living for patients with neuromuscular disease: A systematic review and meta-analysis.Journal of neuromuscular diseases · 2026Pooled it
- Physical training of wheelchair users with neuromuscular disorders: A systematic review.Journal of neuromuscular diseases · 2025Pooled it
- Trial
- Rehabilitation approaches used for children with spinal muscular atrophy: A scoping review based on the F-words framework.Journal of pediatric rehabilitation medicine · 2026Article
- Enhanced terminal sliding mode control for gait exoskeleton device: experimental investigation and validation.Scientific reports · 2026Article
- Assist and resist: a dual-track framework for pediatric exoskeleton rehabilitation.Frontiers in pediatrics · 2026Article
- [Gross Motor Function after Rehabilitation with the Atlas 2030 Pediatric Exoskeleton in Children With Cerebral Palsy].Revista de neurologia · 2025Observational
- ChMER: an exoskeleton robot with active body weight support walker based on compliant actuation for children with cerebral palsy.Frontiers in bioengineering and biotechnology · 2025Article
- Usability and Safety of the ATLAS 2030 Robotic Gait Device in Children with Cerebral Palsy and Spinal Muscular Atrophy.Children (Basel, Switzerland) · 2024Article
- An Exoskeleton Design and Numerical Characterization for Children with Duchenne Muscular Dystrophy.Bioengineering (Basel, Switzerland) · 2024Article
- Rehabilitation for spinal muscular atrophy patients in China: a national cross-sectional study.Orphanet journal of rare diseases · 2024Article
- Preliminary Virtual Constraint-Based Control Evaluation on a Pediatric Lower-Limb Exoskeleton.Bioengineering (Basel, Switzerland) · 2024Article
- [Recent research on home rehabilitation and nursing for spinal muscular atrophy].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024Review
- Enhancing walking efficiency of adolescents with neurological impairments using an exosuit for ambulatory activities of daily living.Frontiers in robotics and AI · 2024Article
- Benefits of robotic gait assistance with ATLAS 2030 in children with cerebral palsy.Frontiers in pediatrics · 2024Article
- Design and Control of a Single-Leg Exoskeleton with Gravity Compensation for Children with Unilateral Cerebral Palsy.Sensors (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundChildren with spinal muscular atrophy (SMA) present muscle weakness and atrophy that results in a number of complications affecting their mobility, hindering their independence and the development of activities of daily living. Walking has well-recognized physiological and functional benefits. The ATLAS 2030 exoskeleton is a paediatric device that allows gait rehabilitation in children with either neurological or neuromuscular pathologies with gait disorders. The purpose is to assess the effects in range of motion (ROM) and maximal isometric strength in hips, knees and ankles of children with SMA type II after the use of ATLAS 2030 exoskeleton.
methodsThree children (mean age 5.7 ± 0.6) received nine sessions bi-weekly of 60 min with ATLAS 2030. ROM was assessed by goniometry and strength by hand-held dynamometer. All modes of use of the exoskeleton were tested: stand up and sit down, forward and backward walking, and gait in automatic and active-assisted modes. In addition, different activities were performed during the gait session. A descriptive analysis of all variables was carried out.
resultsThe average time of use was 53.5 ± 12.0 min in all sessions, and all participants were able to carry out all the proposed activities as well as to complete the study. Regarding isometric strength, all the measurements increased compared to the initial state, obtaining the greatest improvements for the hip flexors (60.2%) and extensors muscles (48.0%). The ROM increased 12.6% in hip and 34.1% in the ankle after the study, while knee ROM remained stable after the study.
conclusionImprovements were showed in ROM and maximal isometric strength in hips, knees and ankles after using ATLAS 2030 paediatric gait exoskeleton in all three children. This research could serve as a preliminary support for future clinical integration of ATLAS 2030 as a part of a long-term rehabilitation of children with SMA.
trial registrationThe approval was obtained (reference 47/370329.9/19) by Comunidad de Madrid Regional Research Ethics Committee with Medical Products and the clinical trial has been registered on Clinical Trials.gov: NCT04837157.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.